Sanuwave Will Host a Conference Call on November 7, 2025 at 8:30 AM (ET) to Present Q3 2025 Financial Results

Sanuwave Health, Inc. (NASDAQ: SNWV), a frontrunner in the development of FDA-approved wound care solutions, has announced it will host a live conference call on November 7, 2025, at 8:30 AM Eastern Time to discuss its financial results for the third quarter of 2025. The call provides an opportunity for investors and analysts to gain insights into the company's performance and future prospects.

Participants can join the call by dialling 1-800-274-8461 for toll-free access, or 1-203-518-9814 for international callers. Those preferring an instant connection can click on the provided link to access the event directly. Supporting materials related to the conference call will be available on Sanuwave's investor relations webpage to facilitate a comprehensive understanding of the company’s financial situation.

The replay of the conference will be accessible until November 28, 2025, through a designated call-in option, allowing those who cannot attend the live call to stay informed.

Sanuwave specializes in innovative non-invasive medical systems aimed at repairing and regenerating skin, musculoskeletal tissue, and vascular structures. The company's portfolio includes a range of regenerative medicine products designed to enhance the body's natural healing processes across various medical disciplines, including wound healing, orthopedics, aesthetics, and cardiac interventions.

Investors should note that the upcoming call may include forward-looking statements reflecting the company's expectations regarding future operations, financial performance, and potential growth. Sanuwave cautions that such statements inherently involve risks and uncertainties, with actual results possibly differing from forecasts. As always, stakeholders are encouraged to review the company’s regulatory filings for a comprehensive understanding of challenges that may impact ongoing performance.

For further inquiries, interested parties are invited to contact Sanuwave’s investor relations team via email at investors@sanuwave.com.

Sanuwave Health, Inc. (NASDAQ: SNWV) is set to host a conference call on November 7, 2025, at 8:30 AM (ET) to present its Q3 2025 financial results. As an investor or analyst, this event is pivotal for evaluating the company's financial trajectory and operational insights, particularly in the context of its specialized focus on next-generation FDA-approved wound care products.

Given that Sanuwave’s offerings revolve around innovative energy transfer technologies that enhance the body's natural healing processes for conditions such as wound healing, orthopedics, and cardiovascular health, investors should closely monitor the conference call for updates on sales performance, cost management, and advancements in product development. Any indications of revenue growth or increased market penetration, particularly in a growing healthcare sector focused on regenerative medicine, could be bullish for the stock.

Additionally, the press release mentions the presence of forward-looking statements, emphasizing that results could vary due to numerous factors, including regulatory oversight and competition. Investors should take heed of this caution and consider these risks when interpreting the forthcoming results.

For those tracking the company's performance metrics, accessing the Q3 report and accompanying materials available on Sanuwave’s investor relations website will provide a comprehensive understanding of their current standing and future prospects. The emphasis on R&D and commercialization could support long-term growth, assuming they continue to navigate potential regulatory challenges effectively.

In summary, with the upcoming conference call presenting an opportunity for Sanuwave to outline its financial health and future directions, investors should remain alert to both optimistic and cautionary signals that emerge, aligning their investment positions accordingly based on the company's performance narratives.